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The aim of this study was to develop new soy protein drug delivery matrix systems by melt-processing
techniques, namely, extrusion and injection moulding. The soy matrix systems with an encapsulated drug
(theophylline, TH) were previously compounded by extrusion performed at two different pH values, (i) pH
4 (SIpDtp) and (ii) pH 7 (SIDtp), and further injection-moulded into a desired shape. During the extrusion
process the matrixes SIDtp were also cross-linked with glyoxal (0.6X-SIDtp) and reinforced with a bioactive
filler, hydroxylapatite (SI-HADtp). The obtained mouldings were used to study the drug-release mechanisms
from the plastic soy-TH matrixes. In an isotonic saline solution (ISS) buffered at pH 5.0 (200 mM acetate
buffer), the resulting release kinetics could be described using the Fick’s second law of diffusion. Because
the diffusion coefficients were found to be constant and the boundary conditions to be stationary, these
systems are drug-diffusion controlled. Conversely, the dominant phenomena in an isotonic saline solution
buffered at pH 7.4 (200 mM Tris/HCl buffer) are more complex. In fact, because of the higher polymer
solubility, the resulting matrix is time-variant. So, the drug release is affected by swelling, drug diffusion,
and polymer dissolution, being faster when compared to ISS-200 mM acetate buffer, pH 5.0. The changes
in the formulation composition affecting the correspondent release rates were also investigated. At pH 7.4,
increasing the cross-linking degree of the polymer matrix (via reaction with glyoxal or heat treatment) or
decreasing the net charge (extruding at pH near its isoelectric point) led to lower release rates. The
incorporation of ceramic filler caused the opposite effect. Because of the low solubility of the matrix at pH
5.0, no significant variations were detected with variations in the selected formulations. These systems,
based on a nonstandard protein-based material, seem to be very promising to be used as carriers for drug
delivery.
1. Introduction
The most conventional way to make matrix drug delivery
systems is based on the compression of polymer-drug
mixtures into a compact form (e.g., slabs and tablets).1-3
Alternatively, the drugs can be previously granulated with
the polymer so that the drug particles are covered with a
layer aiming at retarding the respective release process.4,5
In other studies, drugs have also been incorporated into the
polymer granulates using techniques such as (i) solvent
evaporation,6 (ii) polymer solution granulation,7 (iii) melt
granulation,8 and (iv) sintering.9 The obtained granulates were
then compressed into slabs or tablets. However, the release
kinetics was found to be greatly dependent on the compaction
properties of the polymer-drug granules.6-9 Other alterna-
tives include the design of matrix drug delivery systems in
which the drug particles are dispersed in a melted polymeric
phase. A common example is the compression of drug-filled
polymeric compounds above the melting point of the polymer
to form a solid part containing the drug.10-12 In this type of
device, the release kinetics is controlled by the polymer bulk
properties and not by the porosity of the system.
A less-frequent methodology is the encapsulation of a drug
into a polymer extrudate that will be subsequently shaped
in the final geometry by injection moulding. The major
advantages over the more-conventional above-described
methods are (i) continuity of the production process because
the different production steps (mixing, melting, homogeniz-
ing, and shaping) are carried out in a single equipment, (ii)
cost-effective process because the technique usually offers
high throughputs, low material loss, and excellent homoge-
neity, (iii) high geometrical freedom, (iv) environmental
friendliness because no organic solvent is used during the
processing stage, (v) possibility to work in clean room
conditions, and (vi) high versatility in terms of materials and
formulations.10,11,13-15
Following this last described approach, soy protein was
chosen as the matrix former because of its high availability
and biodegradability,16 good melt processability,17 high
thermal stability,17 and noncytotoxicity.18 Its outstanding
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feasibility has been established by a variety of applications
in the polymer, food, and agriculture fields.19-21 Although
it is also used as a cosmetic aid22 and was proposed to be
used in the biomedical field,23,24 no applications have been,
to our knowledge, proposed on what concerns to the use of
soy for the production of melt-extruded or injection-moulded
drug/matrix compounds.
Therefore, this work was developed with the objective to
explore the possibility to encapsulate a drug into a soy matrix
by melt extrusion and subsequently study its suitability to
be used as a drug delivery system. The release behavior of
the obtained devices was investigated for a range of
formulations to evaluate the effect of parameters such as the
cross-linking degree, the matrix net charge, and the presence
of bonelike ceramic reinforcements.
2. Experimental Section
2.1. Materials. The following materials were used as
received from the manufacturers: soy protein isolate (amor-
phous, 83.4% protein w/w on dry basis, Loders Crocklaan
BV, The Netherlands), glycerol, glyoxal (40% v/v aqueous
solution), o-phthaldialdehyde (OPA, Sigma-Aldrich Chemie
BV, Zwijndrecht, The Netherlands), and theophylline anhy-
drous (TH, C7H8N4O2, Mw ) 180.2 g/mol, mp 270-274 °C,
solubility 1 g/120 mL H2O (RT), purity > 98%, Figure 1,
Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands).
Hydroxylapatite (a nonsintered bonelike ceramic filler with
an average particle size < 20 ím) was supplied by CAM
Implants BV, Leiden, The Netherlands. All of the other
reagents used in the experiments were of analytical grades.
Glyoxal was the selected cross-linker because of its
dialdehyde functionality able to react with the free -amine
groups of the lysine (or hydroxylysine) residues of soy
protein (eq 1):
Moreover, glyoxal has shown to be less toxic for the human
cells than the most commonly used formaldehyde and
glutaraldehyde cross-linkers when used to cross-link protein-
based matrixes such as collagen.25
2.2. Premix Preparation. Premixes of the matrix material
(soy protein isolate), filler, and drug were prepared prior to
processing. The constituents of each formulation were
weighed and transferred into a mixer container. This was
followed by mixing all of the compounds for 15 min at room
temperature (25 °C) using a Bear Varimixer (Bear, Denmark)
equipped with a low-shear spiral-mixing tool at a speed of
45 rpm.
2.3. Melt Extrusion. The solid premixes were converted
into plastic materials with encapsulated TH by extrusion.26
They were directly fed into a corotating twin-screw extruder
(Berstorff, Hannover, Germany, D ) 25 mm and L ) 40D).
The liquids, such as plasticizers (glycerol and water (or a
buffer solution of acetic acid (CH3COOH)/sodium acetate
(CH3COONa) 200 mM, pH 4)) and cross-linker (glyoxal),
were concurrently injected into the second feeding zone of
the extruder barrel with a piston pump (Pro Minet, Verder
BV, The Netherlands). Table 1 presents all of the formula-
tions prepared during this experiment and the respective
codes. The following extrusion conditions, based on pre-
liminary research work, were used: a screw speed of 200
rpm and a temperature profile of 50-70-80-80-80-80-
80-80-80-50 °C (from the hoper to the die).
The obtained extrudates were cooled to room temperature
and cut into pellets. Prior to further analysis they were dried
for 24 h at 60 °C.
2.4. Sample Preparation. Dumbbell-like specimens (4 
10 mm2 of cross section) were injection-moulded in a
DEMAG D25 NC IV machine under optimized and steady
processing conditions, namely, barrel temperatures ranging
from 120 to 140 °C, injection pressure of 2500 bar, and 100
mm/s injection speed during 5.0 s of injection time.
A batch of the injection-moulded specimens was subjected
to a thermal treatment performed at 80 °C during 24 h in an
air-circulating oven (24TT-SIDtp). Subsequently, all of the
specimens (SIDtp, 0.6X-SIDtp, 24TT-SIDtp, SIpDtp, and SI-
HADtp) were conditioned at 25 °C and 60% relative humidity
(RH) for at least 1 week before testing (ISO 483:1998 (E)).
2.5. Sample Characterization. 2.5.1. Morphology. The
mouldings morphology was assessed by observation of the
respective sections (parallel to the flow direction) using an
Table 1. Compositions of the Investigated Matrixesa
formulation
SItp SIDtp 0.6X-SIDtp 24TT-SIDtpb SIpDtp SI-HADtp
soy 100 100 100 100 100 100
glycerol 10 10 10 10 10 10
water 30 30 30 30 30 30
glyoxal 0.6
theophylline 20 20 20 20 20
hydroxylapatite 30
pH 7.0 7.0 7.0 7.0 4.0 7.0
free amine group content (%) 97.6 ( 0.5 55.9 ( 1.0 72.2 ( 1.1
a All quantities in parts/100 g protein (phg). Abbreviations: SItp, thermoplastic soy matrix; SIDtp, thermoplastic soy matrix with encapsulated theophylline;
0.6X-SIDtp, glyoxal cross-linked thermoplastic soy matrix with encapsulated theophylline; 24TT-SIDtp, thermal-treated thermoplastic soy matrix with
encapsulated theophylline; SIpDtp, thermoplastic soy matrix with encapsulated theophylline extruded at pH 4; SI-HADtp, hydroxylapatite reinforced
thermoplastic soy matrix with encapsulated theophylline. b Subjected to thermal treatment, 24 hrs/80 °C.
Figure 1. Chemical structure of theophylline anhydrous (TH,
C7H8N4O2).
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Olympus SZ-ET stereoscope magnifier. The respective
photographs were taken using an Olympus DP 11 digital
camera. Figure 2 illustrates a typical section of the moulding
SIDtp showing the utility of the production methodology to
form homogeneous drug dispersions.
2.5.2. Cross-Linking Degree. The cross-linking degree of
the produced specimens was evaluated through the quanti-
fication of the reduction of the respective free amine group
content. This was determined using the OPA (o-phthaldial-
dehyde) method.27 A 50 íL aliquot of a solution containing
2 g/L of protein powder dissolved in sodium tetraborate
buffer (0.0125 M + 2% SDS) was added directly to 1.0 mL
of OPA reagent in a cuvette. The resulting solution was
mixed rapidly and incubated for 2 min at room temperature
before the absorbency was read at 340 nm against water.
The determination of the free amine groups of each sample
was achieved through a calibration curve previously estab-
lished using L-leucine as a standard.
2.6. Drug Release Studies. The release kinetics of the
model drug TH from the soy matrixes was also assessed.
Randomly selected batches of specimens were immersed at
37 °C in isotonic saline solutions (ISS, NaCl 9 g/L-1%
sodium azide (NaN3)) buffered at two different pHs: (i) pH
5.0 ( 0.03, 0.2 M acetic acid (CH3CO2H)/0.2 M sodium
acetate (CH3CO2Na) buffer; (ii) pH 7.4 ( 0.02, 0.2 M tris-
(hydroxymethyl) aminomethane/0.2 M hydrochloric acid
(HCl) buffer (0.2 M Tris-HCl buffer). The 1% sodium azide
was used to avoid the growth of unwanted microorganisms.
The experiments were performed in a horizontal shaker (GFL
3033, Gesellschaft, Burgwedel, Germany) at 100 rpm.
At preset times, 1 mL of every solution was taken out
and replaced by 1 mL of fresh solution. The solution was
then carefully filtered using a Microcon filter (Amicon, The
Netherlands) of 10 kD mesh. The supernatant was assayed
for released of TH at 273 nm using an Alliance HPLC-UV
system (Water Chromatography BV, The Netherlands)
coupled with a Waters 2690 separations module and a Waters
996 photodiode array detector. The selected mobile phase
corresponded to a mixture of water/acetronitrile (80:20 v/v)
used at a flow rate of 0.75 mL/min. A Chrompack Varian
Hypersyl 5 ím ODS column of 150 mm  4.6 mm was
used in combination with a 1 cm precolumn. All experiments
were conducted in triplicate.
The total drug loading of the samples was also determined
using the above-described HPLC system. Ten milligrams of
each sample, previously pulverized, were dissolved in 100
mL of ethanol. A 100 íL aliquot of this solution was injected
onto the column to determine the theophylline concentration.
Using these data, we calculated the percentage of theophyl-
line in the sample versus the theoretical concentration.
2.7. Solubility Determination. An excess amount of TH
was placed in contact with ISS-acetate buffer, pH 5.0, and
ISS-Tris/HCl buffer, pH 7.4, to determine its solubility in
these release media. The samples were shaken for 24 h at
37 °C. After convenient centrifugation, the supernatant was
filtered through a 0.45 ím syringe filter. Aliquots of the
filtrate liquids were analyzed for TH by HPLC-UV as
described previously (section 2.6).
2.8. Wet and Dry Weight Studies. Pure soy matrix (SI)
specimens were immersed as described in section 2.6. They
were weighed at time t ) 0 (initial weight). The bars were
withdrawn from the release media (ISS-Tris/HCl for pH
7.4 or ISS-CH3COOH/CH3COONa for pH 5.0) at prede-
termined time intervals. They were sequentially weighed in
the wet state (wet weight) and dried to constant weight in a
vacuum oven at 40 °C during 24 h (ISO 62:1980 (E)) (dry
weight). All experiments were also performed in triplicate.
Figure 2. General SIDtp moulding morphology.
Figure 3. Release kinetics of theophylline from a soy matrix SIDtp (]) in an ISS-acetate buffer, pH 5.0, and (b) in an ISS-Tris/HCl buffer, pH
7.4 (ISS ) isotonic saline solution, 9 g/L NaCl-1% sodium azide (NaN3)).
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2.9. Release Kinetics. Assuming perfect sink conditions,
homogeneous initial drug distribution, and constant diffu-
sivity and considering only drug diffusion, the diffusion
process for specimens with rectangular parallelepiped-
geometry and composed of materials following the Fick’s
second law can be described by eq 2:28
where D is diffusion coefficient of the drug, Mt and M∞ are
the amount of drug released at time t and t ) ∞, respectively,
and ap, bp, and cp denote the rectangular parallelepiped
lengths along the x-, y- and z-axes, respectively. In the present
studied case, ap ) 10 mm, bp ) 14ap, and cp ) ap/2.5.
To simplify eq 2, the rectangular cross sections of the
rectangular parallelepiped specimens were converted into
circular cross sections (cylindrical specimen). This correction
was based on the hydraulic radius concept (Rc )
x(apcp/ð)).
Figure 4. Dry and wet weight of a soy matrix SIDtp versus time (4,0) in an ISS-acetate buffer, pH 5.0, and (2,9) in an ISS-Tris/HCl buffer,
pH 7.4 (ISS ) isotonic saline solution, 9 g/L NaCl-1% sodium azide (NaN3)).
Figure 5. Modeling theophylline release from a soy matrix SIDtp (4) in an ISS-acetate buffer, pH 5.0, and ([) in a ISS-Tris/HCl buffer, pH 7.4
(ISS ) isotonic saline solution, 9 g/L NaCl-1% sodium azide (NaN3)). Fit of the pure diffusion model (considering drug transport only with












exp(- (2m + 1)2ð2ap2 Dt) ∑n)0∞ 1(2n + 1)2 
exp(- (2n + 1)2ð2bp2 Dt) ∑p)0∞ 1(2p + 1)2 exp(- (2p + 1)2ð2cp2 Dt)
(2)
Table 2. Apparent Drug Diffusion Coefficients, D, Predicted Using
Mt/M∞ ) 1 - exp(-(8/Rc2)Dt)a
apparent diffusion coefficient, D  10-5 (cm2/min)
pH SIDtp 0.6X-SIDtp 24TT-SIDtpb SIpDtp SI-HADtp
5.0 4.29 ( 0.02 2.86 ( 0.02 2.54 ( 0.01 3.17 ( 0.02 2.54 ( 0.04
7.4 30.5 ( 0.4 12.4 ( 0.1 12.9 ( 0.1 21.3 ( 0.1 37.5 ( 0.3
a Abbreviations: SIDtp, thermoplastic soy matrix with encapsulated
theophylline; 0.6X-SIDtp, glyoxal cross-linked thermoplastic soy matrix with
encapsulated theophylline; 24TT-SIDtp, thermal-treated thermoplastic soy
matrix with encapsulated theophylline; SIpDtp, thermoplastic soy matrix
with encapsulated theophylline extruded at pH 4; SI-HADtp, hydroxylapa-
tite-reinforced thermoplastic soy matrix with encapsulated theophylline.
b Subjected to thermal treatment, 24 hrs/80 °C.
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Taking into account radial, as well as axial, mass transfer,
the cumulative amount of drug released versus time for the
cylinder of radius Rc and height Hc (Hc ) bp) is given by eq
3:28
where qV are the roots of the Bessel function of the first kind
of order zero (eq 4):28
Because the ratio height/radius is higher than 10,28 a
simplification concerning the dimensionality of the problem
is possible: the axial mass transfer in the cylinder can be
negligible compared with the radial mass transfer. Conse-
quently, eq 3 can be approximated by eq 5:28
Equation 5 can be solved for the Bessel function of first type,
zero order, and four roots (V ) 4)
resulting in the following expression:
Figure 6. Effect of the difference of cross-linking degree of the amine groups between the matrixes SIDtp and 0.6X-SIDtp on (a) theophylline
drug release kinetics and (b) theophylline release rates when immersed in an ISS-acetate buffer, pH 5.0, and in an ISS-Tris/HCl buffer, pH













exp(- qV2Rc2Dt) ∑n)0∞ 1(2n + 1)2 exp(- (2n + 1)2ð2Hc2 Dt) (3)


















) 1 - exp(- 8Rc2Dt) (7)
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The release data obtained for all of the soy matrixes were
compared with predictions of the above-described equation.
3. Results and Discussion
3.1. Drug Release from Soy Matrix with Encapsulated
TH (SIDtp). Figure 3 illustrates the pH-dependent release
of TH from the soy matrix SIDtp in the two solutions used:
ISS-acetate buffer, pH 5.0, and ISS-Tris/HCl buffer, pH
7.4. In ISS-acetate buffer, pH 5.0, the drug was completely
released within a 56 h time period. However, with ISS-
Tris/HCl buffer, pH 7.4, the maximum release was 52%,
reached immediately after 4 h of immersion. This difference
in maximum release was attributed to the amphoteric nature
of the polymer. Soy is almost insoluble at pH 5.0 because
its net charge is approximately zero (isoelectric point of soy
is 4.3-4.8). Consequently, polymer-drug interactions tend
to be minimal, and the maximum release can reach 100%.
In contrast, at pH 7.4 the net charge is negative. So, it is
expected that the TH is linked (or interacts) with the
negatively charged polymer matrix, inhibiting the respective
release process (48% nonreleased material). This difference
in the release rates can also be related with the coefficient
of diffusion of the TH for the two different pHs because the
drug solubility in both media is similar: 22.0 ( 0.5 and 18.9
( 0.8 mg/mL at pH 7.4 and 5.0, respectively.
The behavior of the pure polymer used as a matrix (SI)
within both release media was also examined, including its
swelling and weight loss profiles. The changes in dry and
wet weight of SI bars in ISS-acetate buffer, pH 5.0, and in
ISS-Tris/HCl buffer, pH 7.4, are plotted against time in
Figure 4. As expected, at lower pH the SI dry weight
remained nearly constant because the polymer solubility
under these conditions is low. Interestingly, the water uptake
Figure 7. Effect of difference in cross-linking degree due to thermal treatment between the matrixes SIDtp and 24TT-SIDtp on (a) theophylline
drug release kinetics and (b) theophylline release rates when immersed in an ISS-acetate buffer, pH 5.0, and in an ISS-Tris/HCl buffer, pH
7.4 (ISS ) isotonic saline solution, 9 g/L NaCl-1% sodium azide (NaN3)). SDs were within (0.10 in all cases.
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rate was high, reaching equilibrium at both pHs after 4 h of
immersion. In addition, the volume of the matrixes remained
almost constant during this time period. Therefore, because
perfect sink conditions were assured during drug release,
stationary boundary conditions can be considered to describe
the drug diffusion process.
As it can be observed from Figures 2 and 3, at pH 5 water
uptake is fast compared with drug diffusion. Pure SI matrixes
are saturated within 4 h, whereas drug release does not
exceed 38% after this time. Thus, the drug diffusivity can
be assumed to be constant and equal to the diffusivity in the
fully wetted system.
Conversely, at pH 7.4 water uptake is synchronized with
the drug diffusion. Pure SI matrixes are fully wetted within
4 h, the time necessary for the complete drug diffusion.
Accordingly, the diffusivity of the drug is dependent on the
buffer diffusion through the matrix.
Under these conditions and considering the initial homo-
geneous distribution of the drug through the specimen, the
Fick’s second law (eq 2) can be approximated by the
analytical solutions described by eq 7. Figure 5 shows the
fits of eq 7 to the experimentally determined drug release
data. Good agreement was achieved when the release was
performed at pH 5, indicating the validity of this model for
this system (r2 ) 0.9893). The apparent diffusion coefficient
of theophylline in the ISS-acetate buffer, pH 5.0, wetted
soy matrix was determined assuming a value of 4.29  10-5
cm2/min (Table 2). Not as good agreement was found for
the studies performed at pH 7.4 (r2 ) 0.9755). This is mainly
due to the time-variant matrix structure, nonconstant drug
diffusivities, and dependence of drug diffusivity on the buffer
diffusivity. Nevertheless, the apparent diffusion coefficient
of theophylline in the ISS-Tris/HCl buffer, pH 7.4, wetted
soy matrix was estimated (3.05  10-4 cm2/min, Table 2).
Figure 8. Effect of the differences in net charge between the matrixes SIDtp and SIpDtp on (a) theophylline drug release kinetics and (b)
theophylline release rates when immersed in an ISS-acetate buffer, pH 5.0, and in an ISS-Tris/HCl buffer, pH 7.4 (ISS ) isotonic saline
solution, 9 g/L NaCl-1% sodium azide (NaN3)). SDs were within (0.15 in all cases.
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In conclusion, drug release from SIDtp bars in ISS-acetate
buffer (pH 5.0) is purely drug-diffusion-controlled, whereas
in ISS-Tris/HCl buffer (pH 7.4), the water uptake kinetics
have to be taken in consideration.
3.2. Influence of Formulation. 3.2.1. Cross-Linking
Degree. Figures 6A and 7A show the effect of the cross-
linking degree on the resulting drug release rate. Increasing
the amine group cross-linking degree from 2.5% (SIDtp) to
27.8% (24TT-SIDtp) and to 44.1% (0.6X-SIDtp) (Table 1)
causes a reduction of the TH release rate in ISS-Tris/HCl
buffer, pH 7.4. This can be attributed to differences in the
matrix structure. At high pH, a less-cross-linked polymer
matrix allows drug diffusion more efficiently than a more
tightly cross-linked structure, leading to increased diffusion
rates (Table 2). At pH 7.4, a 42% cross-linking degree (0.6X-
SIDtp) (Table 1) resulted in about 60% reduction of the
apparent diffusion coefficient (Table 2), when compared with
the non-cross-linked material.
The thermal-treated matrixes proved to promote a more
effective reduction in the drug release rate. In fact, a 25%
cross-linking degree (24TT-SIDtp, Table 1) directs a reduction
of the apparent diffusion coefficient (Table 2) of about 60%
(at pH 7.4) when compared with SIDtp. This behavior can
be explained by the two different types of cross-linking that
may coexist in the soy material: (i) reaction with the amine
groups of lysine (or hydroxylysine) residues (27.8% cross-
linking, Table 1) and (ii) formation of disulfide bonds by
oxidation of the thiol groups of cysteine residues (maximum
30% cross-linking through cysteine residues, eq 8).
However, at low pH values (ISS-acetate buffer, pH 5), the
Figure 9. Effect of the differences in percentage of matrix reinforcement between the matrixes SIDtp and SI-HADtp on (a) theophylline drug
release kinetics and (b) theophylline release rates when immersed in an ISS-acetate buffer, pH 5.0, and in an ISS-Tris/HCl buffer, pH 7.4 (ISS
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matrixes are fairly soluble; thus, the drug diffusion rates are
slower and almost independent of the degree of cross-linking
of the matrix. Nevertheless, at pH 7.4, increasing the cross-
linking degree of the polymer matrix is a possible route to
adjust the system to the individual needs of the drug.
Depending on the pharmacokinetics of the drug to be
administered, this effect might be more or less important.
3.2.2. Net Charge. Because the isoelectric point of soy
ranges between pH 4.2 and 4.8, the extrusion performed at
pH 4.0 (formulation 4) was intended to produce matrixes
with a net charge lower than that obtained using water as a
plasticizer (pH  6.8). In general, the release rates of SIpDtp
and SIDtp were rather similar both in ISS-acetate buffer,
pH 5.0, and ISS-Tris/HCl buffer, pH 7.4 (Figure 8A).
However, at high pH, the total release for SIpDtp is smaller
than that for SIDtp (Figure 8B). This effect must be related
to the leaching of acetic acid from the sample and consequent
reduction of the dissolution medium pH during the release
tests.
3.2.3. Matrix Reinforcement. The addition of 30% of
hydroxylapatite to the matrix led to a significant acceleration
of drug release in ISS-Tris/HCl buffer, pH 7.4 (Figure 9A,B
and Table 2). This can be attributed to the lack of polymer-
reinforcement interactions in these composites.26 Therefore,
the drug will easily diffuse through the open polymer-
ceramic interfacial regions and be released out of the matrix.
At low pH, no significant differences in the release rates
were found.
Thus, the choice of the appropriate type of matrix is an
important point in determining the performance of the drug-
matrix system. Depending on the type of drug and desired
release profile, the matrix bulk material has to be carefully
selected.
4. Conclusions
A new type of polymeric matrix that can be used in
controlled release applications has been developed using
melt-based processing techniques, such as extrusion and
injection moulding. This two-step route allows for the
encapsulation of a drug and the production of a moulded
part without any subsequent finishing operations. The major
advantages of these systems are as follows: (i) ease of
production (especially at industrial scale); (ii) suitability for
a large variety of polymeric matrixes; (iii) applicability to
different types of drugs; (iv) biodegradability. The in situ
modification of the matrix during processing by cross-linking,
changing of net charge, or filler reinforcement appeared to
be possible ways to adjust the material release patterns.
Further, these new protein matrixes showed a pH-sensitive
behavior, which increases their possibility for application as
controlled delivery devices to carry a range of bioactive
agents.
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